Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.

Christian LohrmannEileen M O'ReillyJoseph A O'DonoghueNeeta Pandit-TaskarJorge A CarrasquilloSerge K LyashchenkoShutian RuanRebecca TengWolfgang ScholzPaul W MaffuidJason S LewisWolfgang A Weber

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Our study shows that the tumor antigen CA19-9 secreted to the circulation can be used for sensitive detection of primary tumors and metastatic disease by immuno-PET. This significantly broadens the number of molecular targets that can be used for PET imaging and offers new opportunities for noninvasive characterization of tumors in patients.

Keyphrases

pet imaging
sensitive detection
positron emission tomography
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
squamous cell carcinoma
small cell lung cancer
quantum dots
prognostic factors
computed tomography
patient reported outcomes